Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in patients with end-stage renal disease

被引：0
|
作者：
Auer, Johann [1 ,2 ,3 ]
Auer, Lisa [4 ]
机构：
[1] St Josef Hosp, Dept Cardiol & Intens Care, Braunau, Austria
[2] Kepler Univ Hosp, Dept Cardiol & Intens Care, Linz, Austria
[3] Paracelsus Med Univ, Salzburg, Austria
[4] Med Univ Graz, Dept Expt Cardiol, Graz, Austria
来源：
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION | 2024年 / 54卷 / 09期
关键词：
CHRONIC KIDNEY-DISEASE; RISK;
D O I：
10.1111/eci.14262
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in dialysis patients
    Torino, Claudia
    Carbone, Federico
    Pizzini, Patrizia
    Mezzatesta, Sabrina
    D'Arrigo, Graziella
    Gori, Mercedes
    Liberale, Luca
    Moriero, Margherita
    Michelauz, Cristina
    Fre, Federica
    Isoppo, Simone
    Gavoci, Aurora
    La Rosa, Federica
    Scuricini, Alessandro
    Tirandi, Amedeo
    Ramoni, Davide
    Mallamaci, Francesca
    Tripepi, Giovanni
    Montecucco, Fabrizio
    Zoccali, Carmine
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2024, 54 (09)
  • [2] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors
    Avci, Ahmet
    Demir, Kenan
    Altunkeser, Bulent Behlul
    [J]. TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2014, 42 : 56 - 67
  • [3] Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
    Leong, Derek
    Wu, Peter E.
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (32) : E894 - E894
  • [4] PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9): A Narrative Review
    Dua, Pamila
    Reeta, K. H.
    [J]. JOURNAL OF THE PRACTICE OF CARDIOVASCULAR SCIENCES, 2020, 6 (03) : 226 - 233
  • [5] Regulation of ENaC by proprotein convertase subtilisin/kexin type 9(PCSK9)
    Sharotri, Vikas
    Snyder, Peter M.
    [J]. FASEB JOURNAL, 2010, 24
  • [6] PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Goes "DAMP"
    Silverstein, Roy L.
    [J]. CIRCULATION, 2021, 143 (01) : 62 - 64
  • [7] Role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in diabetic complications
    Imaralu, Omonzejie E.
    Narasimhulu, Chandrakala Aluganti
    Singal, Pawan K.
    Singla, Dinender K.
    [J]. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2024, 102 (01) : 14 - 25
  • [8] Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
    Rainer Schulz
    Klaus-Dieter Schlüter
    Ulrich Laufs
    [J]. Basic Research in Cardiology, 2015, 110
  • [9] Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
    Schulz, Rainer
    Schlueter, Klaus-Dieter
    Laufs, Ulrich
    [J]. BASIC RESEARCH IN CARDIOLOGY, 2015, 110 (02)
  • [10] Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
    Shahreyar, Muhammed
    Salem, Salem A.
    Nayyar, Mannu
    George, Lekha K.
    Garg, Nadish
    Koshy, Santhosh K. G.
    [J]. JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2018, 31 (04) : 628 - 634
12345